2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1225

Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Abstract Number: 1226

Assessing the Possible Association of Anti-TNF Use with New Neoplasms: An Important Methodological Consideration
Abstract Number: 1227

Discrepancies Between Registered and Published Primary Outcomes in Randomized Controlled Trials of Rheumatoid Arthritis
Abstract Number: 1228

Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink
Abstract Number: 1229

Regional Variation in Measured Detection of Ankylosing Spondylitis
Abstract Number: 1230

Only One-Third of Patients with Spondyloarthritis Are Managed By Rheumatologists
Abstract Number: 1231

The Prevalence of Non-Radiographic Axial Spondyloarthritis Among Patients with Inflammatory Back Pain in Rheumatology Practices
Abstract Number: 1232

Prevalence of Idiopathic Inflammatory Myopathies in Sweden in 2012 – a National Register Study
Abstract Number: 1233

Epidemiology of GCA in Bergen (Western Norway) 1972-2012
Abstract Number: 1234

Epidemiology of Sarcoidosis 1976-2013: A Population-Based Study
Abstract Number: 1235

Epidemiology of Kikuchi-Fujimoto Disease in Martinique and Characteristics in an Afro-Caribbean Population: Close Relation with Lupus
Abstract Number: 1236

Google-Driven Search for Autoimmune Big Data Links Air Pollution and Younger Age at Diagnosis of Systemic Lupus Erythematosus: Geoepidemiological Analysis of 171,000 Adult Patients
Abstract Number: 1237

The Incidence and Prevalence of Systemic Lupus Erythematous in a Defined Population in United Arab Emirates
Abstract Number: 1238

Incident Systemic Lupus Erythematosus in Males in a Northern California County Hospital
Abstract Number: 1239

Significant Impact of Microrna-Target Gene Networks on the Genetics of Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].